Aveo Oncology Inc., of Cambridge, Mass., said its development partner, Eusa Pharma Ltd., of Hemel Hempstead, U.K., has submitted its responses to the EMA Day 120 list of questions issued by the Committee for Medicinal Products for Human Use as part of the centralized review process of the marketing authorization application for tivozanib for the first-line treatment of advanced renal cell carcinoma.